Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Traws Pharma (TRAW) Research & Development (2016 - 2025)

Historic Research & Development for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $2.3 million.

  • Traws Pharma's Research & Development fell 5480.15% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 3320.42%. This contributed to the annual value of $12.8 million for FY2024, which is 1239.72% up from last year.
  • According to the latest figures from Q3 2025, Traws Pharma's Research & Development is $2.3 million, which was down 5480.15% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Traws Pharma's Research & Development ranged from a high of $5.1 million in Q3 2024 and a low of $1.7 million during Q4 2021
  • In the last 5 years, Traws Pharma's Research & Development had a median value of $2.3 million in 2025 and averaged $2.6 million.
  • Per our database at Business Quant, Traws Pharma's Research & Development plummeted by 6151.3% in 2021 and then soared by 11621.78% in 2022.
  • Traws Pharma's Research & Development (Quarter) stood at $1.7 million in 2021, then skyrocketed by 116.22% to $3.8 million in 2022, then crashed by 35.49% to $2.4 million in 2023, then fell by 23.66% to $1.9 million in 2024, then grew by 24.38% to $2.3 million in 2025.
  • Its Research & Development stands at $2.3 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.5 million for Q1 2025.